Navigation Links
Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology

BOSTON--(BUSINESS WIRE)--May 1, 2007 - Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) announced that positive data from a Phase II clinical study of Rituxan(R) (rituximab) in patients with relapsing-remitting multiple sclerosis (RRMS) were presented today at the American Academy of Neurology annual meeting held in Boston. Rituxan is a therapeutic antibody that targets and selectively depletes CD20-positive B-cells.

"There remains a great need for safe and effective treatments for patients with RRMS," said Stephen Hauser, MD, Professor and Chair, Department of Neurology, University of California, San Francisco. "These Phase II results are very encouraging and suggest B-cells play a key role in MS. They also lend support to the concept that selective targeting of B-cells may be an important approach to treating this debilitating disease."

In this Phase II double-blind, placebo-controlled study that evaluated the safety and efficacy of Rituxan in adult patients with RRMS, 104 patients were randomized to receive either a single treatment course of Rituxan (two infusions separated by two weeks) or placebo. The primary endpoint was defined as the total number of gadolinium-enhancing T1 lesions at weeks 12, 16, 20 and 24, as measured by serial MRI scans of the brain. The total number of gadolinium lesions at weeks 12, 16, 20 and 24 was statistically significantly reduced in patients receiving Rituxan compared to those receiving placebo (p less than 0.0001). At week 24, the total cumulative mean number of gadolinium lesions per patient was reduced by 91 percent, to 0.5 in the Rituxan-treated group from 5.5 in the placebo group.

In addition, the proportion of patients with relapses over 24 weeks in the Rituxan-treated arm was 14.5 percent compared to 34.3 percent in the placebo arm (58 percent relative reduction) (p = 0.0238).

With the exception of infusion associated adverse events,
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... VRUS ), a clinical stage pharmaceutical company ... treat viral,infections, reported unaudited financial results for the ... Pharmasset reported a net loss,attributable to common stockholders ... first fiscal quarter of 2008, as compared to ...
... Software & Database Developed in West ... Treatment Options, VENLO, Netherlands and GRAND RAPIDS, ... (CMM) today announced the formation of a,collaborative effort ... Prime Standard: QIA) to support research focused on ...
Cached Medicine Technology:Pharmasset Reports First Fiscal Quarter 2008 Financial Results 2Pharmasset Reports First Fiscal Quarter 2008 Financial Results 3Pharmasset Reports First Fiscal Quarter 2008 Financial Results 4Pharmasset Reports First Fiscal Quarter 2008 Financial Results 5Pharmasset Reports First Fiscal Quarter 2008 Financial Results 6Pharmasset Reports First Fiscal Quarter 2008 Financial Results 7Pharmasset Reports First Fiscal Quarter 2008 Financial Results 8QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 2QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 3QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 4
(Date:7/10/2014)... Colo. (July 8, 2014) A new study from ... modest improvements, poor oral health remains a major problem ... , "The oral health among Native Americans is abysmal ... rest of the country," said Terrence Batliner, DDS, MBA, ... Research at the School of Public Health. "The number ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Nature, not nurture, ... of individual chimpanzees, a new study finds. "As ... comes to cognitive [thinking] abilities in chimpanzees," William Hopkins ... said in a news release from the journal ... insight into the evolution of intelligence in humans, Hopkins, ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Adults with dyslexia are more ... children or teenagers than people who don,t have the ... Dyslexia, which affects up to 10 percent of people, ... 35 percent of adults with this condition said they ... percent of those without dyslexia. "Even after accounting ...
(Date:7/10/2014)... Kristen Fischer HealthDay ... Slimming down may help ease the hot flashes that often ... debilitating for more than 50 percent of menopausal women, said ... and reproductive science at the Icahn School of Medicine at ... menopausal women experience more than 10 hot flashes a day, ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July ... that break out regularly between outspoken celebrities or loudmouth pundits ... relationship, a new study suggests. High amounts of Twitter ... the couple is in a long-term relationship, according to findings ... turn, that friction can lead to cheating and breakups, the ...
Breaking Medicine News(10 mins):Health News:Study finds widespread oral health problems among Navajo 2Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3
... Patient Care Model Significantly Improves Patient OutcomesEL SEGUNDO, ... provider of kidney care services for those diagnosed ... findings of a study revealing DaVita,s IMPACT(TM) (Incident ... program can significantly reduce mortality rates for new ...
... Pediatric surgeons are able to repair complex heart defects ... but that doesn,t necessarily mean a happy ending for ... great quality of life and others, with the same ... pediatric medical centers throughout the United States shows that ...
... HOUSTON (March 29, 2009) The allergen breathed in by ... MMP7 that activates a cascade of events to prompt an ... College of Medicine ( www.bcm.edu ) in Houston in a ... Immunology . , In particular, MMP7 activates interleukin 25, a ...
... the same for bare metal or drug-eluting devices, study found, ... that stent thrombosis, a blood clot inside a stent, is ... no difference in the clot risk for either drug-eluting ... After a heart attack, many patients undergo a treatment ...
... Health Ltd. affiliate program is the answer for individuals who want to ... benefits as well as demand. ZEO Health has created a risk-free, ... today and find out more about the affiliate program. , ... New ...
... Michael Harbut, M.D., MPH, co-director of the National ... Barbara Ann Karmanos Cancer Institute in Detroit, MI, and ... Wayne State University , announced the use of ... asbestos-related lung disease. The announcement was made at the ...
Cached Medicine News:Health News:DaVita's IMPACT Program Reduces Mortality for New Dialysis Patients 2Health News:DaVita's IMPACT Program Reduces Mortality for New Dialysis Patients 3Health News:Physicians mending broken hearts 2Health News:No Increase in Clots With Drug-Eluting Stents 2Health News:No Increase in Clots With Drug-Eluting Stents 3Health News:ZEO Health's New Program Offers Answer for Those Looking for Income 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 3
Nitinol Flat Wire Basket...
A breakaway microwell EIA for the detection of toxins produced by Enterohemorrhagic E. coli...
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Medicine Products: